VivoSeq
Oncology

Cancer Pain

81

Pipeline Programs↗

11

Active Trials↗

46

Companies Involved↗

Cancer Pain is a moderately active landscape with 81 programs across 46 companies. The most active players are Novartis, Tetra Bio-Pharma, Shenyang Sunshine Pharmaceutical Co., LTD.. 22 therapies are approved with 24 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

67/100

Pipeline Velocity

22/100

Mech. Concentration

32/100

Completion Rate

74/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

Phase 1T

Tetra Bio-Pharma

2 programs

Phase 2S

Shenyang Sunshine Pharmaceutical Co., LTD.

1 program

Phase 2M

MetaPhore Pharmaceuticals

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 2Kyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical14

Methadone

Hikma Pharmaceuticals LLC

Olanzapine

MODAG GmbH

Duloxetine

Alnylam Pharmaceuticals

Naloxegol

Averitas Pharma, Inc.

Ziconotide

Terezinha de Jesus Esteves Barata

Phase 14

Oxcarbazepine

Novartis

Methadone Hydrochloride

National Institute of Allergy and Infectious Diseases (NIAID)

NP2

Diamyd Inc

Hawthorn Red Pigment

Fujian Cancer Hospital

Phase 217

Psilocybin

COMPASS Pathways

Lenalidomide

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Caffeine

Hikma Pharmaceuticals LLC

Intranasal Ketamine

Javelin Pharmaceuticals

Incobotulinumtoxina

Merz Pharmaceuticals GmbH

Phase 324

Morphine Sulfate

Merck & Co.

Fentanyl Citrate

INSYS Therapeutics Inc

Tanezumab

Pfizer

Methylprednisolone

Pfizer

Tramadol Hydrochloride

Haisco Pharmaceutical Group Co., Ltd.

Approved22

Hydromorphone

Rhodes Pharmaceuticals, L.P.

Oxycodone

Protega

Dronabinol

Alnylam Pharmaceuticals

Buprenorphine

Indivior Inc.

Cannabidiol

Jazz Pharmaceuticals

Analysis

Modality Breakdown

96%

Small molecule

90 of 94 classified programs — the dominant modality here.

4%ALL OTHERSProtein / enzyme22%Monoclonal antibody11%Peptide11%

Small molecule leads; the ring shows all 94 classified programs, each share of the total. Modality classified for 100% of 95 pipeline programs.

Analysis

Trial Status

116

clinical trials

Completed65 · 56%
Unknown status17 · 15%
Terminated16 · 14%
Withdrawn7 · 6%
Recruiting6 · 5%
Not yet recruiting4 · 3%
Other1 · 1%

Clinical Trials

Trial Activity

116 trials

Psilocybin in Cancer Pain Study
Recruiting·—·Phase 2·NCT06001749·15 enrolled
Ziconotide for Non-cancer Pain by Intrathecal Administration
Recruiting·EESTEVE Pharmaceuticals SAS·N/A·NCT06541184·85 enrolled
Paracetamol in Addition to WHO Step III Opioids in Chronic Cancer Pain Control
Recruiting·IInsel Gruppe AG, University Hospital Bern·Phase 4·NCT05088876·140 enrolled
Better Options for Chronic Cancer Pain
Recruiting·VVA Office of Research and Development·Phase 4·NCT06574009·294 enrolled
Phase I Study of sss40 Injection for Moderate-to-Severe Bone Metastatic Cancer Pain
Recruiting·SShenyang Sunshine Pharmaceutical Co., LTD.·Phase 1/2·NCT07008703·132 enrolled
Functional Radiosurgery for Easing or Eliminating Debilitating Oncologic Morbidity (FREEDOM)
Recruiting·JJonsson Comprehensive Cancer Center·Preclinical·NCT07605546·19 enrolled
Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 4·NCT04296305·84 enrolled
Hydromorphone With Electroacupuncture and Ear Acupoint Pressing for Refractory Cancer Pain
Not yet recruiting·QQinghai Red Cross Hospital·Phase 1·NCT07489625·30 enrolled
Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain
Not yet recruiting·HHenan Cancer Hospital·Phase 4·NCT06897917·203 enrolled
3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain
Not yet recruiting·33D Medicines·Phase 2·NCT05265052·177 enrolled
Efficacy of Non-opioid Drugs in Addition to Opioid Therapy for Cancer Pain Management: a Double-blind, Randomized, Three Arm, Placebo Controlled Trial Assessing the Key Non-opioids Dipyrone (Metamizole) and Ibuprofen
Not yet recruiting·UUniversity Hospital, Basel, Switzerland·Phase 3·NCT07682558·318 enrolled
An Efficacy and Safety Study of Fentanyl (JNS020QD) in Participants With Cancer Pain
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT00641667·66 enrolled
PROspective Non-interventional Open laBEl Trial for TARGIN in Korean Patients With Cancer Pain
Completed·MMundipharma Korea Ltd·Phase 4·NCT01719757·359 enrolled
The Effectiveness and Tolerability of Fentanyl Matrix in Chronic Non-cancer Pain; Assessment of Patient's Pain Treatment Goal Achievement
Completed·Johnson & Johnson logoJohnson & Johnson·N/A·NCT01688583·410 enrolled
Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain
Completed·IINSYS Therapeutics Inc·Phase 3·NCT00538863·319 enrolled
Page 1 of 8

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)